Yonsei Med J.
2004 Jun;45(Suppl):S5-S6. 10.3349/ymj.2004.45.Suppl.5.
Government Regulations on Cellular Therapy and Proposed Approach Related with These Products by KFDA
- Affiliations
-
- 1Division of Biologics Pharmaceutical Safety Bureau, Korea Food and Drug Administration, Seoul, Korea. yoomy7020@kfda.go.kr
- KMID: 1726137
- DOI: http://doi.org/10.3349/ymj.2004.45.Suppl.5
Abstract
- Advances in biomedical technology has enabled the research and use of novel therapies in cellular transplantation. A number of trials using chondrocyte and autologous skin products are underway and will soon become commercially available for clinical utilization. However, the Korea Food and Drug Administration currently lack systematic regulations for efficacy and safety evaluation of the emerging therapies. Specifically, dose related studies are uncontrolled and availability of clinical research centers is inadequate. Thus, patients are receiving therapy without guidelines for indication, dose, and adequate safety profiles. We propose criteria for cases in which these therapies can be used and advocate IRB determined quality assurance for future research.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Regulatory Problems in Radionuclide Therapy and Suggestions for Systematic Improvement
- Developmental Strategy for Stem Cell Therapy Products in Regulatory Considerations
- Clinical trials for vaccine development in registry of Korea Food and Drug Administration
- The Government Policies of New Tobacco Products: Strategies for Managing Electronic Cigarettes and Heated Tobacco Products
- Establishing an Effective Governance System Is the Top Priority in Securing Competitiveness in the Biohealth Industry
